2017 Press Releases

Keyword Search
 
2017 | 2016 | 2015
DateTitle 
04/06/17FibroGen, Inc. Announces Pricing of Follow-On Offering of Common Stock
SAN FRANCISCO, April 06, 2017 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ:FGEN), a science-based biopharmaceutical company, today announced that the company has priced an underwritten follow-on offering, which is expected to raise gross proceeds of approximately $120 million. FibroGen is offering 5,228,750 shares of its common stock at an offering price of $22.95 per share, before underwriting discounts and commissions. All of the shares are being offered by FibroGen. The offering is expecte... 
Printer Friendly Version
03/31/17FibroGen Announces China FDA Approval of CTA to Conduct Pivotal Phase 2/3 Clinical Trial of Roxadustat in Anemia Associated With Lower Risk MDS
Expands Roxadustat Development Program Into Oncology-Related Anemia in China SAN FRANCISCO, March 31, 2017 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ:FGEN), a science-based biopharmaceutical company, today announced the approval by the China Food and Drug Administration (CFDA) of the Company’s clinical trial application (CTA) in China for a Phase 2/3 pivotal trial of roxadustat in anemia associated with lower risk myelodysplastic syndromes (MDS). FibroGen and AstraZeneca (NYSE:AZN) are collab... 
Printer Friendly Version
03/30/17Positive Results Published in Nephrology Dialysis Transplantation From Two China Phase 2 Trials of Roxadustat for Treatment of Anemia in Chronic Kidney Disease
Findings are Consistent with China Phase 3 Trials Results, and Support China NDA Submission SAN FRANCISCO, March 30, 2017 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ:FGEN), a science-based biopharmaceutical company, today announced that clinical results from two Phase 2 studies in China of roxadustat for the treatment of anemia in patients with chronic kidney disease (CKD) were published in the journal Nephrology Dialysis Transplantation. In these studies, in dialysis-dependent, and in non-dia... 
Printer Friendly Version
03/01/17FibroGen Reports Fiscal 2016 Financial Results
Conference Call and Webcast to be Held Today at 4:30 p.m. Eastern Time/1:30 p.m. Pacific Time SAN FRANCISCO, March 01, 2017 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ:FGEN), a science-based biopharmaceutical company, today reported financial results for the year ended December 31, 2016, and provided an update on the company’s recent developments. “We are pleased with the topline results reported from our two China Phase 3 trials, which are the first Phase 3 readouts for roxadustat, and bri... 
Printer Friendly Version
02/22/17FibroGen to Report Fiscal 2016 Financial Results on March 1, 2017
Conference Call and Webcast Scheduled for 4:30 p.m. ET (1:30 p.m. PT) SAN FRANCISCO, Feb. 22, 2017 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ:FGEN), a science-based biopharmaceutical company, today announced that it will report financial results for the year ended December 31, 2016, on Wednesday, March 1, 2017, after market close, and will host a conference call to discuss financial results and provide a business update at 4:30 p.m. ET (1:30 p.m. PT). Audio Webcast Interested parties may... 
Printer Friendly Version
02/03/17FibroGen Announces Publication of Pamrevlumab (FG-3019) Clinical Data in Pancreatic Cancer Showing Safety and Improved Survival Outcomes in Combination with Chemotherapy
Higher pamrevlumab exposure associated with improved survival SAN FRANCISCO, Feb. 03, 2017 (GLOBE NEWSWIRE) -- FibroGen, Inc., (NASDAQ:FGEN), a science-based biopharmaceutical company, today announced that clinical results from the company’s open-label, dose-escalation Phase 1/2 study (FGCL-MC3019-028) of pamrevlumab in pancreatic cancer were published in the Journal of Cancer Clinical Trials (Picozzi et al., J Cancer Clin Trials 2017, 2:123). The published results support a dose-related incr... 
Printer Friendly Version
01/30/17FibroGen’s Roxadustat (FG-4592) Meets Primary Endpoints in Two Phase 3 Anemia Studies in China
Roxadustat: effective in dialysis (hemodialysis and peritoneal dialysis) and non-dialysis chronic kidney disease (CKD) patients SAN FRANCISCO, Jan. 30, 2017 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ:FGEN), a science-based biopharmaceutical company, and its subsidiary FibroGen China Medical Technology Development Co., Ltd. (FibroGen China), today reported positive topline results from the two Phase 3 clinical studies of roxadustat (FG-4592 or 罗沙司他[1]) designed to support new drug application ... 
Printer Friendly Version
01/20/17Pamrevlumab Pancreatic Cancer Clinical Data Presented at ASCO 2017 Gastrointestinal Cancers Symposium
Promising safety and efficacy observed in open-label, randomized study SAN FRANCISCO, Jan. 20, 2017 (GLOBE NEWSWIRE) -- FibroGen, Inc. (Nasdaq:FGEN) today announced that updated results from an ongoing clinical study of pamrevlumab (FG-3019) in combination with standard-of-care chemotherapy in patients with locally advanced pancreatic ductal adenocarcinoma (PDAC) were presented in a poster session during the ASCO 2017 Gastrointestinal Cancers Symposium in San Francisco. Pamrevlumab is a fully... 
Printer Friendly Version